ANNEXSupplementary provisions
ANNEX Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows: (1) Table 3.1 is amended as follows: (a) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries: Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) 007-004-00-1 nitric acid … % 231-714-2 7697-37-2 Ox. Liq. 2 Skin Corr. 1A H272 H314 GHS03 GHS05 Dgr H272 H314 EUH071 Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 99 % > C ≥ 65 % B 015-003-00-2 calcium phosphide; tricalcium diphosphide 215-142-0 1305-99-3 Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Eye Dam. 1 Aquatic Acute 1 H260 H300 H311 H330 H318 H400 GHS02 GHS06 GHS05 GHS09 Dgr H260 H300 H311 H330 H318 H400 EUH029 EUH032 M = 100 031-001-00-4 gallium arsenide 215-114-8 1303-00-0 Repr. 1B Carc. 1B STOT RE 1 H360F H350 H372 (respiratory and haematopoietic systems) GHS08 Dgr H360F H350 H372 (respiratory and haematopoietic systems) 050-008-00-3 tributyltin compounds, with the exception of those specified elsewhere in this annex — — Repr. 1B Acute Tox. 3 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H360FD H301 H312 H372** H315 H319 H400 H410 GHS08 GHS06 GHS09 Dgr H360FD H301 H312 H372** H315 H319 H410 * STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,25 % ≤ C < 1 % Skin Irrit. 2; H315:C ≥ 1 % Eye Irrit. 2; H319:C ≥ 1 % M = 10 A 1 603-102-00-9 1,2-epoxybutane 203-438-2 106-88-7 Flam. Liq. 2 Carc. 2 Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 H225 H351 H302 H312 H332 H335 H315 H319 GHS02 GHS08 GHS07 Dgr H225 H351 H302 H312 H332 H335 H315 H319 603-197-00-7 tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol 403-640-2 107534-96-3 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H361d*** H302 H400 H410 GHS08 GHS07 GHS09 Wng H361d*** H302 H410 M = 1 M = 10 606-054-00-7 isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone — 141112-29-0 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 H361d*** H400 H410 GHS08 GHS09 Wng H361d*** H410 M = 10 M = 100 607-197-00-8 nonanoic acid 203-931-2 112-05-0 Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 H315 H319 H412 GHS07 Wng H315 H319 H412 613-042-00-5 imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1 H -imidazole 252-615-0 35554-44-0 Carc. 2 Acute Tox. 3 Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 1 H351 H301 H332 H318 H410 GHS08 GHS06 GHS05 GHS09 Dgr H351 H301 H332 H318 H410 M = 10 613-057-00-7 dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine 216-474-9 1593-77-7 Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H361d H373 (liver) H314 H317 H400 H410 GHS08 GHS05 GHS07 GHS09 Dgr H361d H373 (liver) H314 H317 H410 EUH071 M = 1 M = 1 613-133-00-X etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole 219-991-8 2593-15-9 Carc. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H317 H410 M = 1 M = 1 613-149-00-7 pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one 405-700-3 96489-71-3 Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 H331 H301 H400 H410 GHS06 GHS09 Dgr H331 H301 H410 M = 1 000 M = 1 000 (b) the following entries are inserted in accordance with the order of the entries set out in Table 3.1: Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) 019-003-00-3 potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 Eye Irrit. 2 H319 GSH07 Wng H319 604-092-00-9 phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2] 310-154-3 [1] 121158-58-5 [1] 74499-35-7 [2] Skin Corr. 1C Aquatic Acute 1 Aquatic Chronic 1 H314 H400 H410 GHS05 GHS09 Dgr H314 H410 M = 10 M = 10 606-148-00-8 carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] Skin Sens. 1 H317 GHS07 Wng H317 606-149-00-3 tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione — 335104-84-2 Repr. 2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361d H373 (eyes, kidneys, liver) H317 H400 H410 GHS08 GHS07 GHS09 Wng H361d H373 (eyes, kidneys, liver) H317 H410 M = 100 M = 10 607-707-00-9 fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate — 71283-80-2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H373 (kidneys) H317 H400 H410 GHS08 GHS07 GHS09 Wng H373 (kidneys) H317 H410 M = 1 M = 1 607-708-00-4 octanoic acid 204-677-5 124-07-2 Skin Corr. 1C Aquatic Chronic 3 H314 H412 GHS05 Dgr H314 H412 607-709-00-X decanoic acid 206-376-4 334-48-5 Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 H315 H319 H412 GHS07 Wng H315 H319 H412 607-710-00-5 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear 271-093-5 68515-50-4 Repr. 1B H360FD GHS08 Dgr H360FD 607-711-00-0 spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate — 203313-25-1 Repr. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H361fd H335 H319 H317 H400 H410 GHS08 GHS07 GHS09 Wng H361fd H335 H319 H317 H410 M = 1 M = 1 607-712-00-6 dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate 250-778-2 31717-87-0 Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Chronic 1 H361d H373 (liver) H314 H317 H410 GHS08 GHS05 GHS07 GHS09 Dgr H361d H373 (liver) H314 H317 H410 EUH071 M = 1 607-713-00-1 fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate — 134098-61-6 Acute Tox. 3 Acute Tox. 2 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H301 H330 H317 H400 H410 GHS06 GHS09 Dgr H301 H330 H317 H410 M = 100 M = 1 000 607-714-00-7 triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate — 126535-15-7 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 100 M = 10 607-715-00-2 bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate 442-820-5 149877-41-8 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H373 H317 H400 H410 GHS08 GHS07 GHS09 Wng H373 H317 H410 M = 1 M = 1 613-319-00-0 imidazole 206-019-2 288-32-4 Repr. 1B Acute Tox. 4 Skin Corr. 1C H360D H302 H314 GHS08 GHS07 GHS05 Dgr H360D H302 H314 613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 218-499-0 2164-08-1 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 10 M = 10 616-213-00-2 mandipropamid (ISO); 2-(4-chlorophenyl)- N -{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide — 374726-62-2 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 1 616-214-00-8 metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide — 139528-85-1 Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H373 (eyes, kidneys) H400 H410 GHS08 GHS09 Wng H351 H373 (eyes, kidneys) H410 M = 1 000 M = 100 616-215-00-3 dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide — 163515-14-8 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H317 H400 H410 GHS07 GHS09 Wng H302 H317 H410 M = 10 M = 10 616-216-00-9 flonicamid (ISO); N -(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide — 158062-67-0 Acute Tox. 4 H302 GHS07 Wng H302 616-217-00-4 sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide — 946578-00-3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 M = 1 M = 1 (2) Table 3.2 is amended as follows: (a) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries: Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes 007-004-00-1 nitric acid … % 231-714-2 7697-37-2 O; R8 C; R35 O; C R: 8-35 S: (1/2-)26-28- 36/37/39-45-63 O; R8: C ≥ 65 % C; R35: C ≥ 20 % C; R34: 5 % ≤ C < 20 % B 015-003-00-2 calcium phosphide; tricalcium diphosphide 215-142-0 1305-99-3 F; R15/29 T+; R26/28 Xn; R21 R32 Xi; R38-41 N; R50 F; T+; N R: 15/29-21-26/28-32-38-41-50 S:(1/2-)26-28-30-36/37/39-43-45-60-61 N; R50: C ≥ 0,25 % 031-001-00-4 gallium arsenide 215-114-8 1303-00-0 Repr. Cat. 2; R60 Carc. Cat. 2; R45 T; R48/23 T R: 45-48/23-60 S: 45-53 E 050-008-00-3 tributyltin compounds, with the exception of those specified elsewhere in this annex — — Repr. Cat. 2; R60-61 T; R25-48/23/25 Xn; R21 Xi; R36/38 N; R50-53 T; N R: 21-25-36/38-48/23/25-50/53-60-61 S: 45-53-60-61 T; R25: C ≥ 2,5 % Xn; R22: 0,25 % ≤ C < 2,5 % Xn: R21: C ≥ 1 % T; R48/23/25: C ≥ 1 % Xn; R48/20/22: 0,25 % ≤ C < 1 % Xi; R36/38: C ≥ 1 % N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % A 1 603-102-00-9 1,2-epoxybutane 203-438-2 106-88-7 F; R11 Carc. Cat. 3; R40 Xn; R20/21/22 Xi; R36/37/38 F; Xn R: 11-20/21/22-36/37/38-40- S: (2-)9-16-29-36/37-46 603-197-00-7 tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol 403-640-2 107534-96-3 Repr. Cat. 3; R63 Xn; R22 N; R50-53 Xn; N R: 22-50/53-63 S: (2-)22-36/37-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 % 606-054-00-7 isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl- p -tolyl ketone — 141112-29-0 Repr. Cat. 3; R63 N; R50-53 Xn; N R: 50/53-63 S: (2-)36/37-60-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 607-197-00-8 nonanoic acid 203-931-2 112-05-0 Xi; R36/38 N; R51-53 Xi; N R: 36/38-51/53 S: (2-)46-61 613-042-00-5 imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1 H -imidazole 252-615-0 35554-44-0 Carc. Cat. 3; R40 Xn; R20/22 Xi; R41 N; R51-53 Xn; N R: 20/22-40-41-51/53 S: (2-)26-36/37/39-46-61 613-057-00-7 dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine 216-474-9 1593-77-7 Repr. Cat. 3; R63 C; R34 R43 N; R50-53 C; N R: 34-43-50/53-63 S: (1/2-)26-28-36/37/39-45-60-61 C; R34: C ≥ 10 % Xi; R36/37/38: 5 % ≤ C < 10 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 613-133-00-X etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole 219-991-8 2593-15-9 Carc. Cat. 3; R40 Xn; R22 R43 N; R50-53 Xn; N R: 22-40-43-50/53 S: (2-)36/37-46-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 613-149-00-7 pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one 405-700-3 96489-71-3 T; R23/25 N; R50-53 T; N R: 23/25-50/53 S: (1/2-)36/37-45-60-61 N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52-53: 0,00025 % ≤ C < 0,0025 % (b) the following entries are inserted in accordance with the order of the entries set out in Table 3.2: Index No International Chemical Identification EC No CAS No Classification Labelling Concentration Limits Notes 019-003-00-3 potassium (E,E)-hexa-2,4-dienoate 246-376-1 24634-61-5 Xi; R36 Xi R: 36 S: (2-)25-46 604-092-00-9 phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2] 310-154-3 [1]-[2] 121158-58-5 [1] 74499-35-7 [2] C; R34 N; R50-53 C; N R: 34-50/53 S: (1/2-)26-36/37/39-45-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 606-148-00-8 carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] R43 Xi R: 43 S: (2-)24-37 606-149-00-3 tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione 335104-84-2 Repr. Cat. 3; R63 Xn; R48/22 R43 N; R50-53 Xn; N R: 43-48/22-50/53-63 S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 607-707-00-9 fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate — 71283-80-2 Xn; R48/22 R43 N; R50-53 Xn; N R: 43-48/22-50/53 S: (2-)24-37-46-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 607-708-00-4 octanoic acid 204-677-5 124-07-2 C; R34 N; R51-53 C; N R: 34-51/53 S: (1/2-)26-36/37/39-45-61 607-709-00-X decanoic acid 206-376-4 334-48-5 Xi; R36/38 N; R51-53 Xi; N R: 36/38-51/53 S: (2-)25-46-61 607-710-00-5 1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear 271-093-5 68515-50-4 Repr. Cat. 2; R60-61 T R: 60-61 S: 53-45 607-711-00-0 spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate — 203313-25-1 Repr. Cat. 3; R62-63 Xi; R36/37 R43 N; R50-53 Xn; N R: 36/37-43-50/53-62-63 S: (2-)36/37-60-61 Xi; R43: C ≥ 0,1 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 607-712-00-6 dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate 250-778-2 31717-87-0 Repr. Cat. 3; R63 C; R34 R43 N; R51-53 C; N R: 34-43-51/53-63 S: (1/2-)26-28-36/37/39-45-61 C; R34: C ≥ 10 % Xi: R36/37/38: 5 % ≤ C < 10 % 607-713-00-1 fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate — 134098-61-6 T+; R26 Xn; R22 R43 N; R50-53 T+; N R: 22-26-43-50/53 S: (1/2-)28-36/37-45-60-61-63 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 607-714-00-7 triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate — 126535-15-7 Carc. Cat. 3; R40 N; R50-53 Xn; N R: 40-50/53 S: (2-)36/37-60-61 N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % 607-715-00-2 bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate 442-820-5 149877-41-8 R43 N; R50-53 Xi; N R: 43-50/53 S: (2-)24-37-60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % 613-319-00-0 imidazole 206-019-2 288-32-4 Repr. Cat 2; R61 Xn; R22 C; R34 T; C R: 22-34-61 S: 53-45 613-320-00-6 lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione 218-499-0 2164-08-1 Carc. Cat. 3; R40 N; R50-53 Xn; N R: 40-50/53 S: (2-)36/37-60-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 616-213-00-2 mandipropamid (ISO); 2-(4-chlorophenyl)- N -{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide — 374726-62-2 N; R50-53 N R: 50/53 S: 60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 % 616-214-00-8 metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide — 139528-85-1 Carc. Cat. 3; R40 Xn; R48/22 N; R50-53 Xn; N R: 40-48/22-50/53 S: (2-)36/37-46-60-61 N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52/53: 0,00025 % ≤ C < 0,0025 % 616-215-00-3 dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide — 163515-14-8 Xn; R22 R43 N; R50-53 Xn; N R: 22-43-50/53 S: (2-)24-37-60-61 N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % 616-216-00-9 flonicamid (ISO); N -(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide — 158062-67-0 Xn; R22 Xn R: 22 S: (2-)46 616-217-00-4 sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide — 946578-00-3 Xn; R22 N; R50-53 Xn; N R: 22-50/53 S: (2-)60-61 N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 %